In patients with established RA from the DE019 trial, CDAI 55% had the most discriminatory ability in terms of both the lowest P value and the greatest treatment difference at week 24, when comparing PBO+MTX versus ADA+MTX (Fig. 2c and Additional file 1: Table S1). This evidence concerns the gene ADA and rheumatoid arthritis.